Long Focus Capital Management LLC Sells 182,200 Shares of Insmed, Inc. $INSM

Long Focus Capital Management LLC trimmed its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 35.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 338,000 shares of the biopharmaceutical company’s stock after selling 182,200 shares during the quarter. Insmed accounts for approximately 1.6% of Long Focus Capital Management LLC’s holdings, making the stock its 14th biggest holding. Long Focus Capital Management LLC owned approximately 0.16% of Insmed worth $48,675,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Savant Capital LLC bought a new stake in Insmed during the second quarter worth approximately $205,000. PNC Financial Services Group Inc. raised its position in Insmed by 8.8% during the second quarter. PNC Financial Services Group Inc. now owns 11,576 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 933 shares during the period. Creative Planning lifted its stake in shares of Insmed by 0.6% in the 2nd quarter. Creative Planning now owns 72,176 shares of the biopharmaceutical company’s stock valued at $7,264,000 after purchasing an additional 432 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Insmed by 52.1% in the 2nd quarter. Cetera Investment Advisers now owns 31,462 shares of the biopharmaceutical company’s stock worth $3,166,000 after purchasing an additional 10,783 shares during the period. Finally, Kingsview Wealth Management LLC purchased a new position in shares of Insmed in the 2nd quarter worth approximately $228,000.

Insmed Stock Performance

Insmed stock opened at $144.60 on Tuesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The company has a 50 day moving average price of $154.57 and a 200-day moving average price of $166.22. The company has a market capitalization of $31.17 billion, a PE ratio of -22.56 and a beta of 1.13. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same period in the previous year, the company posted ($1.32) EPS. Insmed’s quarterly revenue was up 152.6% compared to the same quarter last year. As a group, equities analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on INSM shares. Roth Mkm raised Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. Truist Financial set a $205.00 price objective on shares of Insmed in a research note on Monday, January 12th. Stifel Nicolaus set a $205.00 price objective on shares of Insmed in a research report on Thursday, February 19th. Wells Fargo & Company reduced their target price on shares of Insmed from $234.00 to $208.00 and set an “overweight” rating on the stock in a research note on Friday, February 20th. Finally, Mizuho lowered their target price on shares of Insmed from $211.00 to $204.00 and set an “outperform” rating for the company in a report on Tuesday, February 24th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Insmed currently has an average rating of “Buy” and an average price target of $205.57.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the sale, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. The trade was a 5.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the completion of the sale, the insider directly owned 41,754 shares of the company’s stock, valued at $7,315,300.80. The trade was a 67.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 189,651 shares of company stock worth $31,784,545 in the last three months. Insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.